Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Янв. 30, 2023

Background Albeit the need for sex-disaggregated results of adverse events after immunization (AEFIs) is gaining attention since COVID-19 pandemic, studies with emphasis on sexual dimorphism in response to vaccination are relatively scarce. This prospective cohort study aimed assess differences incidence and course reported AEFIs between males females Netherlands provides a summary outcomes published literature. Methods Patient over six month period following first BioNTech-Pfizer, AstraZeneca, Moderna or Johnson&Johnson vaccine were collected Cohort Event Monitoring study. Logistic regression was used ‘any AEFI’, local reactions top ten most sexes. Effects age, brand, comorbidities, prior infection use antipyretic drugs analyzed as well. Also, time-to-onset, time-to-recovery perceived burden compared Third, literature review done retrieve vaccination. Results The included 27,540 vaccinees (38.5% males). Females showed around two-fold higher odds having any AEFI pronounced dose nausea injection site inflammation. Age inversely associated incidence, whereas infection, several comorbidities positively associated. slightly females. Discussion this large correspond existing evidence contribute knowledge gain necessary disentangle magnitude effect sex Whilst have significant probability experiencing an than males, we observed that only minor extent different

Язык: Английский

---

Sex, Age, and Comorbidities Are Associated with SARS-CoV-2 Infection, COVID-19 Severity, and Fatal Outcome in a Mexican Population: A Retrospective Multi-Hospital Study

Journal of Clinical Medicine, Год журнала: 2023, Номер 12(7), С. 2676 - 2676

Опубликована: Апрель 3, 2023

People with comorbidities and the male sex are at a higher risk of developing severe COVID-19. In present study, we aim to investigate associated factors for infection, severity, death due COVID-19 in population from Nuevo León, México. Epidemiological data were collected 65 hospitals December 2020 May 2022. A total 75,232 cases compiled which 25,722 positive SARS-CoV-2. Male sex, older age, diabetes, obesity, hypertension infection. addition above-mentioned factors, renal disease, cardiovascular immunosuppression found be increased severity. These as well neurological diseases, also When comparing different variants SARs-CoV-2, variant B1.1.519 probability by 2.23 times compared AY.20 variant. SARS-CoV-2 death. Along aforementioned comorbidities, severity Another factor is presence disease. The increases odds

Язык: Английский

---

Covid-19 vaccination reported side effects and hesitancy among the Syrian population: a cross-sectional study

Annals of Medicine, Год журнала: 2023, Номер 55(2)

Опубликована: Авг. 6, 2023

Introduction Studying post-vaccination side effects and identifying the reasons behind low vaccine uptake are pivotal for overcoming pandemic.Methods This cross-sectional study was distributed through social media platforms face-to-face interviews. Data from vaccinated unvaccinated participants were collected analyzed using chi-square test, multivariable logistic regression to detect factors associated with severe effects.Results Of 3509 included, 1672(47.6%) vaccinated. The most common reason not taking concerns about vaccine's 815(44.4). majority of symptoms mild 788(47.1%), followed by moderate 374(22.3%), 144(8.6%). tiredness 1028(61.5%), pain at injection site 933(55.8%), low-grade fever 684(40.9%). Multivariable analysis revealed that <40 years (vs. ≥40; OR: 2.113, p-value = 0.008), females males; 2.245, p-value< .001), did receive influenza shot last year Influenza 1.697, 0.041), AstraZeneca other brands; 2.799, co-morbidities no co-morbidities; 1.993, diabetes mellitus mellitus; 2.788, 0.007) post-vaccine effects. Serious reported blood clots 5(0.3%), thrombocytopenia 2(0.1%), anaphylaxis 1(0.1%), seizures cardiac infarction 1(0.1%).Conclusion Our in severity self-limiting. Increasing public's awareness nature would reduce misinformation improve trust vaccines. Larger studies evaluate rare serious adverse events long-term needed, so people can have sufficient information understanding before making an informed consent which is essential vaccination.

Язык: Английский

---

Assessment of COVID-19 Vaccine Effectiveness Against SARS-CoV-2 Infection, Hospitalization and Death in Mexican Patients with Metabolic Syndrome from Northeast Mexico: A Multicenter Study

Vaccines, Год журнала: 2025, Номер 13(3), С. 244 - 244

Опубликована: Фев. 27, 2025

Background/Objectives: Metabolic syndrome (MetS) is a predisposing factor for severe COVID-19. The effectiveness of COVID-19 vaccines in patients with MetS has been poorly investigated. aim this study was to evaluate the vaccination before (BO) and after Omicron (AO) SARS-CoV-2 variant MetS. Methods: This retrospective observational carried out total 3194 PCR or rapid antigen test. main outcomes were vaccine against infection, hospitalization death resulting from Results: BO, only two doses BNT162b2 effective lost AO. Also, doses, BNT162b2, ChAdOx1 CoronaVac BO; however, AO, effective. Regarding as an outcome COVID-19, whereas 100% BO presentation sore throat increased regardless type, dyspnea diminished CoronaVac. Conclusions: impacted vaccines’ A tailored scheme should be implemented due varying rates observed our study.

Язык: Английский

---

Self-reported side effects of COVID-19 vaccines among the public

Journal of Pharmaceutical Policy and Practice, Год журнала: 2024, Номер 17(1)

Опубликована: Фев. 27, 2024

The safety, side effects and efficacy profile of COVID-19 vaccines remain subjects ongoing concern among the public in Malaysia. aim this study was to determine types adverse following immunisation with differences based on various raise awareness reduce vaccine hesitancy public. A total 901 Malaysian adults (≥18 years) who received were selected participate our cross-sectional through an online survey between December 2021 January 2022. 814 (90.3%) participants reported ≥1 effect immunisation. Of these, predominant symptoms swelling at injection site (n = 752, 83.5%), headache 638, 70.8%), pain or soreness 628, 69.7%), fatigue tiredness 544, 60.4%), muscle weakness 529, 58.7%) diarrhea 451, 50.1%). Recipients Pfizer-BioNTech (Comirnaty ®) highest number 355, 43.6%), followed by mixed 254, 31.2%), Oxford-AstraZeneca (ChAdOx1-®[recombinant]) 113, 13.9%) Sinovac (CoronaVac®) 90, 11.1%). showed that individuals significantly more elderly age, female gender high educational level [P value < 0.05]. Mixed recipients also local systemic after first dose third when compared other single recipients. This demonstrated self-reported vaccines. These findings may provide different hope educating safety profiles these reducing

Язык: Английский

---

Reported COVID-19 vaccines side effects among Algerian athletes: a comparison between inactivated virus, adenoviral vector, and mRNA COVID-19 vaccines

The Physician and Sportsmedicine, Год журнала: 2023, Номер 52(2), С. 134 - 146

Опубликована: Март 6, 2023

Many types of COVID19 vaccines are administered globally, yet there is not much evidence regarding their side effects among athletes. This study evaluated the selfreported postvaccination inactivated virus, adenoviral vector, and mRNA Algerian

Язык: Английский

---

Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals

Frontiers in Public Health, Год журнала: 2022, Номер 10

Опубликована: Сен. 27, 2022

Importance Most healthcare institutions require employees to be vaccinated against SARS-CoV-2 and many also at least one booster. Objective We determine the impact of vaccine type, demographics, health conditions on COVID-19 side effects in professionals. Design A immunity study was performed 2021 American Association for Clinical Chemistry Annual Scientific meeting. As part this study, a REDCap survey with cascading questions administered from September 9, October 20, 2021. General included participant past present conditions, smoking, exercise, medications. specific asked about status vaccine-associated after each dose including any boosters, previous infection COVID-19, diagnostic testing performed, type severity symptoms COVID-19. Results There were 975 participants (47.1% male, median age 50 years) who completed survey. Pfizer most commonly (56.4%) followed by Moderna (32.0%) Johnson &amp; (7.1%). no significant differences received age, or number prescription Side reported more frequently second (e.g., Pfizer) (54.1%) single/only (47.8%). Males significantly likely report ( p &lt; 0.001), while females injection site reactions fatigue headache muscle pain chills = fever 0.007), nausea 0.001). upward trend reporting increasing trends among different races, ethnicities, medications, smoking exercise. In multivariate logistic regressions analyses, associated higher risk than both single Johnson. Conclusions relevance Younger people, females, those receiving had that per self-report led moderate severe limitations. other studies, increase may explained viral mRNA concentrations but additional protective immunity.

Язык: Английский

---

Evaluation and comparison of post-vaccination adverse effects among Janssen and Oxford-AstraZeneca vaccinated adult individuals in Debre Tabor Town: A cross- sectional survey in Northwest Ethiopia

Human Vaccines & Immunotherapeutics, Год журнала: 2022, Номер 18(6)

Опубликована: Авг. 12, 2022

COVID 19 vaccination has recently been launched globally to halt the pandemic. But vaccines have some adverse effects that raise concerns in global community. This study aimed evaluate and compare of Janssen Oxford-AstraZeneca vaccinated adults. A community-based cross-sectional was conducted from March 15 30, 2022 among 421 (211 210 Astra Zeneca vaccinated) adults recruited by a convenience sampling technique Debre Tabor Town, Northwest Ethiopia. Data were collected via face-to-face interviews reviewing immunization card. Chi-square test, independent

Язык: Английский

---

The impact of comorbidity status in COVID-19 vaccines effectiveness before and after SARS-CoV-2 omicron variant in northeastern Mexico: a retrospective multi-hospital study

Frontiers in Public Health, Год журнала: 2024, Номер 12

Опубликована: Июнь 12, 2024

The end of the coronavirus disease 2019 (COVID-19) pandemic has been declared by World Health Organization on May 5, 2023. Several vaccines were developed, and new data is being published about their effectiveness. However, clinical trials for performed before Omicron variant appeared there are population groups where vaccine effectiveness still needs to be tested. overarching goal present study was analyze effects COVID-19 vaccination after in patients considering comorbidities a from Nuevo Leon, Mexico.

Язык: Английский

---

COVID-19 vaccination hesitance and adverse effects among US adults: a longitudinal cohort study

Frontiers in Epidemiology, Год журнала: 2024, Номер 4

Опубликована: Июль 16, 2024

Introduction Although Coronavirus disease 2019 (COVID-19) vaccination is critical to control its spread, vaccine hesitancy varies significantly among the United States population; moreover, some recipients experienced various adverse effects. We aim assess impact of COVID-19 in a university-affiliated community, factors affecting participants’ decisions, and their Methods A pre-vaccination online Institutional Review Board IRB-approved survey was emailed Nov/Dec 2020, 2 months before implementation state-policy protocols for vaccination. post-vaccination May/June 2021, two after protocol execution. third follow-up sent fourth June/July 2022. The study population included three groups adult participants: university students, faculty, staff-(MS), health system patients-(MP), Cancer Center patients-(MCP). designed as longitudinal cohort study. Statistical analyses were performed using SPSS. Results With combined response rate 26% (40,578/157,292) four surveys, 15,361 participants completed first (MS = 4,983, MP 9,551, MCP 827). 2/3 (63.5%) willing get vaccinated, with significant difference acceptance groups, MS:56.6%, MP:66.2%, MCP:71.6% ( p &lt; 0.05). Vaccine rates reached 89% second vaccine's approval, lower MS:84.6% than MP:90.74% MCP:92.47% Safety effectiveness concerns main decisions all surveys; however, reported these decreased between pre-vaccination, post-vaccination, surveys 87%, 56%, 46%, respectively( More two-thirds (70%) having either minor/moderate symptoms (61.6%) or major (8.6%) getting doses Conclusion hesitance associated regarding safety efficacy. rose higher expected execution, likely due continuous education, whereas efficacy remain hindering acceptance. Continuous education focusing on can reduce raise

Язык: Английский

---